Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

AC Immune SA (ACIU)

8.64   -0.61 (-6.59%) 01-24 16:00
Open: 9.16 Pre. Close: 9.25
High: 9.41 Low: 8.5
Volume: 137,198 Market Cap: 619M
AC Immune SA is a clinical stage biopharmaceutical company. It discovers, designs and develops novel, proprietary medicines for treatment of neurodegenerative diseases with the help of proprietary platforms.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.414 - 9.477 9.477 - 9.53
Low: 8.388 - 8.445 8.445 - 8.492
Close: 8.556 - 8.649 8.649 - 8.727

Technical analysis

as of: 2020-01-24 4:29:19 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 10.71     One year: 11.84
Support: Support1: 7.61    Support2: 6.33
Resistance: Resistance1: 9.17    Resistance2: 10.14
Pivot: 9.38
Moving Average: MA(5): 9.24     MA(20): 9.14
MA(100): 6.79     MA(250): 5.74
MACD: MACD(12,26): 0.30     Signal(9): 0.41
Stochastic oscillator: %K(14,3): 50.32     %D(3): 62.17
RSI: RSI(14): 46.04
52-week: High: 10.96  Low: 3.25  Change(%): -17.4
Average Vol(K): 3-Month: 13714  10-Days: 12644

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
ACIU has closed above bottom band by 1.1%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2019-11-05
AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2019-09-23
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 71.66
Shares Float (M) 26.11
% Held by Insiders 50.94
% Held by Institutions 28.38
Shares Short (K) 406
Shares Short P. Month (K)

Stock Financials

EPS -0.550
Book Value (p.s.) 2.990
PEG Ratio
Profit Margin 45.09
Operating Margin
Return on Assets (ttm) 11.7
Return on Equity (ttm) 20.7
Qtrly Rev. Growth 1349.5
Gross Profit (p.s.) -0.517
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E -15.71
P/E Growth Ratio -0.07
P/BV 2.89
P/S
P/CF

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.